MX9304611A - Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. - Google Patents

Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Info

Publication number
MX9304611A
MX9304611A MX9304611A MX9304611A MX9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A
Authority
MX
Mexico
Prior art keywords
crystalline hydrate
triazolyltiomethyl
clohydrate
cephalosporine
preparation
Prior art date
Application number
MX9304611A
Other languages
English (en)
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX9304611A publication Critical patent/MX9304611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el clorhidrato del ácido 7-beta-[(Z)-(2-amino-4-tiazolil)-2-hidroxiiminoace tamino]-3-cefem-4-carboxílico y su hidrato cristalino, los cuales tienen una potente actividad antibiótica y son de baja toxicidad y farmacéuticamente estables, con lo cual son útiles como ingredientes activo de formulaciones antibióticas clínicamente útiles, y la producción de los mismos.
MX9304611A 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. MX9304611A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
MX9304611A true MX9304611A (es) 1994-02-28

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304611A MX9304611A (es) 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Country Status (23)

Country Link
US (1) US5407929A (es)
EP (1) EP0581552B1 (es)
KR (1) KR100245938B1 (es)
CN (1) CN1037683C (es)
AT (1) ATE165360T1 (es)
AU (1) AU657866B2 (es)
BR (1) BR9303235A (es)
CA (1) CA2101502A1 (es)
DE (1) DE69318077T2 (es)
ES (1) ES2115725T3 (es)
FI (1) FI933391A7 (es)
GR (1) GR3026699T3 (es)
HU (1) HU219637B (es)
IL (1) IL106516A (es)
MX (1) MX9304611A (es)
NO (1) NO303734B1 (es)
NZ (1) NZ248285A (es)
PH (1) PH30109A (es)
PL (2) PL172835B1 (es)
RU (1) RU2118959C1 (es)
TW (1) TW307769B (es)
UA (1) UA37181C2 (es)
ZA (1) ZA935529B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133479A (en) * 2001-02-24 2007-11-30 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CN102285916B (zh) 2003-02-12 2015-02-25 日产化学工业株式会社 匹伐他汀钙的晶形
MXPA05010083A (es) 2003-03-27 2005-11-23 Basilea Pharmaceutica Ag Cefalosporina en forma cristalina.
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN109503584A (zh) * 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
MX2010001821A (es) * 2007-08-17 2010-03-10 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
KR940005636A (ko) 1994-03-22
CA2101502A1 (en) 1994-02-01
IL106516A (en) 1998-06-15
FI933391A0 (fi) 1993-07-29
DE69318077T2 (de) 1998-10-29
NZ248285A (en) 1994-07-26
AU4422793A (en) 1994-02-03
GR3026699T3 (en) 1998-07-31
FI933391L (fi) 1994-02-01
PH30109A (en) 1996-12-27
EP0581552B1 (en) 1998-04-22
HU9302194D0 (en) 1993-10-28
UA37181C2 (uk) 2001-05-15
BR9303235A (pt) 1994-03-01
ES2115725T3 (es) 1998-07-01
US5407929A (en) 1995-04-18
EP0581552A2 (en) 1994-02-02
FI933391A7 (fi) 1994-02-01
RU2118959C1 (ru) 1998-09-20
KR100245938B1 (ko) 2000-04-01
CN1089948A (zh) 1994-07-27
CN1037683C (zh) 1998-03-11
NO303734B1 (no) 1998-08-24
AU657866B2 (en) 1995-03-23
ZA935529B (en) 1994-02-24
IL106516A0 (en) 1993-11-15
PL299870A1 (en) 1994-02-07
PL172835B1 (pl) 1997-12-31
NO932745L (no) 1994-02-01
HUT68602A (en) 1995-06-28
NO932745D0 (no) 1993-07-30
PL172830B1 (pl) 1997-12-31
EP0581552A3 (en) 1994-06-01
DE69318077D1 (de) 1998-05-28
HU219637B (hu) 2001-06-28
ATE165360T1 (de) 1998-05-15
TW307769B (es) 1997-06-11

Similar Documents

Publication Publication Date Title
MX9304611A (es) Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
BR0009176A (pt) Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
MEP10408A (en) Platinum derivative pharmaceutical formulations
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
EP0937459A3 (en) Pharmaceutical compositions for the treatment of ischemic brain damage
BR0313162A (pt) Composto, processo para preparar o mesmo, e, composição farmacêutica
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
ES2054949T3 (es) Precursores de dopamina.
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
IT1271456B (it) Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
JP2000159790A5 (es)
ES2057225T3 (es) Una composicion para la preparacion de una vitamina d3 activa en forma de dosificacion y su procedimiento de preparacion.
ATE261425T1 (de) Erythromycin-derivate mit antibiotischer wirkung
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
IE37250B1 (en) Diazepine derivatives and processes for their production
AR026451A1 (es) Compuestos heterociclicos sililados
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью